The viral infectivity of oncolytic virus products is the basis of treatment, and the previous data have proved that Ancocare's Double-Spear products are susceptible to epithelial cells and have broad-spectrum infectivity.
The R&D team of Ancocare has approximately 40 years of experience in yellow fever virus research, and has continuously published the latest research results on yellow fever virus in top international virology journals for the past 20 years.
a
n
c
o
c
a
r
e